Skip to main content
Log in

PS18 - 2. Quantification of the beta cell mass based on 111In-Exendin imaging in patients with type 1 diabetes and healthy controls

  • Published:
Nederlands Tijdschrift voor Diabetologie Aims and scope

Abstract

Various tests exist to quantify beta cell (BC) function, but do not necessarily provide information on BC mass (BCM), while BCM seems an important predictor of future BC failure. A method for reliable BCM quantification would be a tremendous asset to better elucidate the pathophysiology of type 1 and type 2 diabetes (T1D and T2D), and to determine effects of therapeutic interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wietske Woliner-van der Weg.

Additional information

1 Dept. of Nuclear Medicine, RUNMC, Nijmegen, The Netherlands, 2 Center for Radiopharmaceutical Sciences, Paul Scherrer institute, Villingen-PSI, Switzerland, 3 Dept. of Internal Medicine, RUNMC, Nijmegen, The Netherlands. Email: w.vanderweg@nucmed.umcn.nl

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woliner-van der Weg, W., Brom, M., Janssen, M. et al. PS18 - 2. Quantification of the beta cell mass based on 111In-Exendin imaging in patients with type 1 diabetes and healthy controls. NED. TIJDSCHR. DIABET. 11, 200–201 (2013). https://doi.org/10.1007/s12467-013-0161-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12467-013-0161-0

Keywords